Trials / Completed
CompletedNCT00481455
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
A Single-Center, Open-Label, Phase II, Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With Protracted Oral Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- CASI Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Panzem NCD | 2000 mg q8h, continuous dosing in 28 day cycles |
| DRUG | Temozolomide | Fixed dose |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2007-09-01
- Completion
- 2008-10-01
- First posted
- 2007-06-01
- Last updated
- 2008-11-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00481455. Inclusion in this directory is not an endorsement.